Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia
| Autor: | Ludger Hargarter, Martin Lambert, Veronica Chomskaya, Marjolein Lahaye, Gali Joldygulov, Pierre Cherubin, Andreas Schreiner, Eva-Maria Tsapakis, Vasilis P. Bozikas, Marnina Swarz, Flavio Vischia |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Paranoid schizophrenia Exacerbation International Cooperation Administration Oral Drug Administration Schedule Cohort Studies 03 medical and health sciences 0302 clinical medicine Recurrence Internal medicine Brief Psychiatric Rating Scale Paliperidone Palmitate medicine Humans Adverse effect Psychiatry Biological Psychiatry Psychiatric Status Rating Scales business.industry Middle Aged medicine.disease 030227 psychiatry Hospitalization Psychiatry and Mental health Treatment Outcome Tolerability Schizophrenia Female business 030217 neurology & neurosurgery Cohort study Antipsychotic Agents |
| Zdroj: | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 19(sup3) |
| ISSN: | 1814-1412 |
| Popis: | Partial or non-adherence in patients with schizophrenia is common and increases the risk of relapse. This study explored safety, tolerability and treatment outcomes in patients hospitalised for an exacerbation of schizophrenia initiated on maintenance treatment of once-monthly paliperidone palmitate (PP1M).A 6-week, observational cohort study of patients initiated on PP1M within 3 weeks after hospital admission.Overall, 367 patients were documented, 85.8% with paranoid schizophrenia subtype. Mean time from hospital admission to PP1M initiation was 9.4 ± 7.7 days. Treatment-emergent adverse events were reported by 22.9% of patients. From baseline to endpoint, significant improvements were observed in psychotic symptoms (Brief Psychiatric Rating Scale total score mean change -19.3 ± 12.6, P .0001) and functioning (Personal and Social Performance scale total score mean change 14.3 ± 12.4, P .0001). Overall, 6.0% of patients were very or extremely satisfied with their prior antipsychotic medication at baseline compared with 47.2% very or extremely satisfied with PP1M treatment at endpoint.Initiating PP1M in patients with exacerbated schizophrenia shortly after hospital admission was well tolerated and resulted in statistically significant and clinically relevant improvements in symptoms and patient functioning, suggesting that patients may benefit from early initiation of PP1M during their hospital stay. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|